We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





AACC Survey Finds Nearly Half of All US Labs Still Do Not Have Supplies for Running COVID-19 Tests

By LabMedica International staff writers
Posted on 30 Jul 2020
A new survey of clinical laboratories in the US has found that nearly half of all responding labs still do not have the supplies they need to run COVID-19 tests.

The survey was conducted by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) which has presented its findings to the White House Coronavirus Task Force, calling on the federal government to take a more active role in alleviating this problem, so that labs can increase their testing capacity in the midst of the virus’s latest surge.

As coronavirus cases in the US soar, the country’s labs have continued to work tirelessly to ramp up testing to help bring the pandemic under control. More...
However, even though US labs are now performing an average of 800,000 COVID-19 tests per day, which is double the average daily number of tests performed in late May, labs in many areas are reporting delays of up to a week in getting test results back to patients. These delays render testing essentially useless in acute patient care and in contact tracing. The main cause of these crippling delays is the persistent shortage of testing and other essential supplies.

AACC conducted a survey to determine the full extent of these supply shortages and how they are changing as the pandemic progresses, in the hopes that this information can help guide the federal government’s response. AACC surveyed clinical labs across the US about this issue during three different time periods: May 1-24, June 1-5, and June 24-July 6. The results showed a troubling trend, namely that supply shortages have persisted over the last few months. In May, 58% of all labs surveyed reported problems getting supplies, a figure that only decreased to 46% by early July. Even more worrying was a rise in the number of labs that are unable to process all requested COVID-19 tests within a week because of supply shortages. In early July, 25% of respondents reported this problem, an uptick from 21% of respondents in May.

The specific supplies that labs have the most difficulty obtaining are COVID-19 test kits and the reagents, or chemicals, used to perform these tests. As of early July, 58% of labs reported problems getting test kits, while 46% reported problems getting reagents. 38% of labs also still reported problems getting the nasal swabs used to obtain patient samples for COVID-19 testing. In fact, out of all the items that respondents had difficulty obtaining in May, personal protective equipment (PPE) is the only one that was not in short supply in late June/early July. While 32% of labs had problems getting PPE in May, only 4% reported having this issue in the most recent survey.

“We at AACC are deeply concerned that clinical labs continue to struggle with obtaining the supplies needed to meet our nation’s COVID-19 diagnostic testing demands,” said AACC President Dr. Carmen Wiley. “While we recognize the difficulty the federal government is encountering with this pandemic, we urge the Task Force to use the data from AACC’s survey as a jumping off point to investigate these ongoing shortages, and to use the authority of the federal government to obtain and allocate these vital supplies.”

Related Links:
American Association for Clinical Chemistry (AACC)


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.